Envoy Medical (COCH) CEO awarded 1M RSUs plus 1M options tied to FDA OK
Rhea-AI Filing Summary
Envoy Medical, Inc. filed a Form 4 showing that Chief Executive Officer Brent T. Lucas received significant new equity awards tied to regulatory milestones for the company’s Acclaim cochlear implant. On June 19, 2026, he was granted 1,000,000 Restricted Stock Units, each representing one share of Class A Common Stock. These RSUs will vest if the U.S. Food and Drug Administration grants approval (including conditional approval) for the Acclaim cochlear implant during the performance period from June 19, 2026 to June 18, 2030.
On the same date, Lucas was also granted 1,000,000 stock options to buy Class A Common Stock at an exercise price of $0.634 per share, expiring on June 19, 2036. The filing also lists his existing equity exposure, including 329,946 Class A Common shares held directly and multiple warrants and options with exercise prices ranging from $0.40 to $11.50 per share, which together show a substantial stake linked to the company’s long-term performance.
Positive
- None.
Negative
- None.
Insider Trade Summary
8 transactions reported
Mixed
8 txns
Insider
Lucas Brent T.
Role
Chief Executive Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (right to buy) | 1,000,000 | $0.00 | -- |
| Grant/Award | Restricted Stock Units | 1,000,000 | $0.00 | -- |
| holding | Stock Option (right to buy) | -- | -- | -- |
| holding | Stock Option (right to buy) | -- | -- | -- |
| holding | Warrant (right to buy) | -- | -- | -- |
| holding | Warrant (right to buy) | -- | -- | -- |
| holding | Warrant (right to buy) | -- | -- | -- |
| holding | Class A Common Stock | -- | -- | -- |
Holdings After Transaction:
Stock Option (right to buy) — 1,000,000 shares (Direct);
Restricted Stock Units — 1,000,000 shares (Direct);
Warrant (right to buy) — 110,987 shares (Direct);
Class A Common Stock — 329,946 shares (Direct)
Footnotes (1)
- Options to purchase 659,811 shares vest on 10/15/2023, and 219,938 shares vest pro rata on the 15th of each month thereafter for 36 consecutive months. Options to purchase 50,000 shares vest on 2/5/2027, and 150,000 shares vest pro rata on the 5th of each month thereafter for 36 consecutive months. Options to purchase 250,000 shares vest on 6/19/27, and 750,000 shares vest pro rata on the 19th of each month thereafter for 36 consecutive months. Fully exercisable. The Series A-1 Warrants expire on the earlier of (i) two years from the initial exercise date and (ii) 30 days after the date on which the Company announces that it has submitted a Premarket Approval Application to the Food and Drug Administration (FDA) for its Acclaim CI Device. The Series A-2 Warrants expire on the earlier of (i) five years from the initial exercise date and (ii) 30 days after the date on which the Company announces that it has received FDA approval for its Acclaim CI Device. Each restricted stock unit represents a contingent right to receive one share of Envoy Medical, Inc. Class A Common Stock. All restricted stock units subject to the RSU Award Grant Notice dated June 19, 2026, will vest as of the date of the official notification by the U.S. Food and Drug Administration (FDA) that it has granted approval (including approval with conditions) for its Acclaim cochlear implant, provided that such announcement occurs during the performance period beginning June 19, 2026 and ending on June 18, 2030.
Key Figures
RSU grant size: 1,000,000 units
New stock options: 1,000,000 options at $0.634/share
Common shares held: 329,946 shares
+5 more
8 metrics
RSU grant size
1,000,000 units
Restricted Stock Units granted 06/19/2026
New stock options
1,000,000 options at $0.634/share
Options granted 06/19/2026, expire 06/19/2036
Common shares held
329,946 shares
Class A Common Stock, direct ownership after transactions
Existing option grant
879,749 options at $2.40/share
Stock Option (right to buy), expire 10/15/2033
Additional options
200,000 options at $0.53/share
Stock Option (right to buy), expire 02/05/2036
Low-price warrants
62,500 + 37,500 underlying shares at $0.40
Two warrant positions on Class A Common Stock
Higher-price warrants
110,987 underlying shares at $11.50
Warrant (right to buy), expire 09/29/2028
RSU performance window
06/19/2026–06/18/2030
Period during which FDA approval must occur for RSU vesting
Key Terms
Restricted Stock Units, Stock Option (right to buy), Premarket Approval Application, Acclaim cochlear implant, +2 more
6 terms
Restricted Stock Units financial
"security_title: "Restricted Stock Units""
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
Stock Option (right to buy) financial
"security_title: "Stock Option (right to buy)""
Premarket Approval Application regulatory
"submitted a Premarket Approval Application to the Food and Drug Administration"
A premarket approval application is a formal, data-packed request submitted to regulators to get permission to sell a high-risk medical device. It is like asking for a driver’s license for a complex product: the company must show clinical trial results, safety testing and manufacturing controls to prove the device works and won’t harm people. Investors watch these filings because approval unlocks revenue and sharply reduces the regulatory risk that can halt a product’s commercial launch.
Acclaim cochlear implant technical
"approval for its Acclaim cochlear implant, provided that such announcement occurs"
Series A-1 Warrants financial
"The Series A-1 Warrants expire on the earlier of (i) two years"
Series A-1 warrants are tradable instruments that give their holder the right, but not the obligation, to buy a company’s shares at a preset price for a limited time; they are typically issued alongside a specific financing round labeled “Series A-1.” Think of them like a coupon that lets an investor buy stock at a locked-in price later — if the company’s share price rises above that price the coupon becomes valuable, otherwise it may expire worthless. For investors they matter because exercising warrants can increase potential upside while also diluting existing shareholders and affecting future ownership percentages and share value.
Series A-2 Warrants financial
"The Series A-2 Warrants expire on the earlier of (i) five years"
Series A-2 warrants are a specific class of long‑term options issued by a company that give the holder the right to buy a set number of shares at a pre‑agreed price. Think of them as a coupon for future stock purchases: they can add potential value for the holder if the share price rises, but they also represent potential dilution for existing shareholders and can affect an investor’s ownership and returns when exercised or converted.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What new equity awards did Envoy Medical (COCH) grant its CEO?
Envoy Medical granted CEO Brent T. Lucas 1,000,000 RSUs and 1,000,000 stock options on Class A Common Stock. These awards significantly increase his equity-based compensation tied to the company’s long-term performance and regulatory milestones.
When do the new Envoy Medical (COCH) RSUs for the CEO vest?
The 1,000,000 RSUs vest upon official FDA approval of the Acclaim cochlear implant during June 19, 2026 to June 18, 2030. Vesting depends on receiving approval, including conditional approval, within that performance period.
What is the exercise price of the new stock options granted to Envoy Medical (COCH) CEO?
The new 1,000,000 stock options granted to the CEO have an exercise price of $0.634 per share. They give him the right to buy Envoy Medical Class A Common Stock at that price until their expiration in 2036.
What existing equity holdings does the Envoy Medical (COCH) CEO report?
Brent T. Lucas reports holding 329,946 shares of Class A Common Stock directly. He also holds several warrants and stock options on Class A Common Stock with exercise prices from $0.40 to $11.50 per share, reflecting sizable prior equity exposure.
How are Envoy Medical (COCH) CEO’s new RSUs linked to FDA actions?
The new 1,000,000 RSUs vest only if the FDA grants approval, including approval with conditions, for the Acclaim cochlear implant. That approval must occur between June 19, 2026 and June 18, 2030 for the units to vest.
What other warrants and options are disclosed for Envoy Medical (COCH) CEO?
Disclosed positions include warrants with exercise prices of $0.40 and $11.50, and stock options at $0.53 and $2.40 per share. These instruments relate to Class A Common Stock and have various future expiration dates.